Stewart, S; Seco-Meseguer, E; Diago-Sempere, E; Marín-Candón, A; Carmona, M; Estébanez, M; López-Fernández, LA; Imaz-Iglesia, I; Saiz, MDG; Laserna-Mendieta, EJ; Peiró, AM; Farré, M; Rodriguez-Jimenez, C; Saiz-Rodriguez, M; Sanabria-Cabrera, J; Rosas-Alonso, R; Abad-Santos, F; Pedrosa, L; Carcas, AJ; García, IG; Borobia, AM – 2024 – 10.1136/bmjopen-2024-089823
Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial – BMJ OPEN
por prodriguez | Ene 1, 2024 | Publicaciones - A-09 | 0 Comentarios